Chugai Pharmaceutical Co. Ltd., of Tokyo, said data from hemophilia A patients in a phase I study of bispecific antibody emicizumab, published in The New England Journal of Medicine, demonstrated a clinically acceptable safety profile and a potential benefit for preventing bleeding in patients, both with and without factor VIII inhibitors. Emicizumab is a once-weekly subcutaneous injection and has be designated a breakthrough therapy by the FDA. It’s currently in a phase III study in collaboration with Basel, Switzerland-based Roche AG. Read More
TOKYO – Earnings at major Japanese pharmaceutical companies announced for the first quarter of this year or for the entire fiscal 2015 were mixed at best. Read More
HONG KONG – China is raising the standard of its generics products in a move to help made-in-China drugs grab a larger share of the global market. As part of that process, however, industry observers expect that more than half of the drugs that are currently sold in the market will be eliminated. Read More
HONG KONG – South Korean conglomerate Samsung’s biosimilar arm, Samsung Bioepis Co. Ltd., is well under way in expanding its global presence by pushing multiple blockbuster biosimilars into major markets around the world. Read More
HONG KONG – Data infrastructure building has started quickly after China’s government announced plans to pour billions into the development of precision medicines. A group of leading companies in cloud computing, medical services and genomics have come together to provide the country with a platform essential to the future bloom of precision medicine in the country. Read More
